Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

De Piano M, Manuelli V, Zadra G, Otte J, Edqvist P-, Pontén F, et al. Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases. Oncogene. 2020;39(18):3666-3679.

Patel SS, Kluk MJ, Weinberg OK. NPM1 Biology in Myeloid Neoplasia. Curr Hematol Malig Rep. 2020;15(4):350-359.

Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife. 2020;9.

Zhang T, Na JH, Li S, Chen Z, Zhang G, Pang S, et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.

Rogers WS, Westblade LF, Soave R, Jenkins SG, Van Besien K, Singh HK, et al. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020;71(7):1693-1700.

Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2).

Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression. medRxiv. 2020.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.